Gen-Probe prevails in Bayer viral diagnostics dispute
This article was originally published in Clinica
An arbitrator has sided with San Diego nucleic acid testing (NAT) specialist Gen-Probe in its dispute with Bayer HealthCare over their viral diagnostics collaboration. Edward Wallin, of Judicial Arbitration & Mediation Service (JAMS), determined that Gen-Probe should have a joint right with Bayer to distribute qualitative TMA assays for the detection of hepatitis C and HIV-1.
You may also be interested in...
Organizations like BARDA, CEPI and others are looking to partner with industry to rapidly test, manufacture, package and deploy vaccines and therapeutics, identifying areas they want to work together during BIO’s recent summit.
The economic stress on payers caused by the pandemic will cause a setback in the development of payment approaches for regenerative therapy, Blue Cross Blue Shield executive warns.
An interim final rule posted by the CMS this week widens further a series of telehealth exemptions and lab specimen collection payment provisions it has previously issued to help providers during the COVID-19 pandemic.